- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07909590
A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning
A Multi-country, Retrospective, Real World Observational Study Evaluating the Impact of an Analgesic Product on Quality-of-Life and Daily Functioning
The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning.
Przegląd badań
Szczegółowy opis
This is a multi-country, real-world, observational, cross-sectional survey study. The target population for this survey study comprises individuals who have used Panadol/Dolex for the relief of more than or equal to (>=)1 headache episode in the past 1 month. Eligible participants will be directed to complete an online survey comprising of a series of questions designed to gather data relevant to the research objectives. The study population will be comprised of approximately 2,100 participants across Australia, Malaysia, Colombia, and Kenya.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Haleon Response Center
- Numer telefonu: +441932 95 95 00
- E-mail: ww.clinical-trial-register@haleon.com
Lokalizacje studiów
-
-
Marina Centre
-
Singapore, Marina Centre, Singapur
- Virtual site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Residents of Australia, Malaysia, Colombia, Kenya who have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month and have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
Opis
Inclusion Criteria:
- Residents of Australia, Malaysia, Colombia, Kenya.
- Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month.
- Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
- Self-reported healthy individuals.
- Able to provide informed consent.
- The specific Panadol/Dolex variant for each country as applicable.
Exclusion Criteria:
- Participants who experience headaches that occur 15 or more days per month.
- Participants with migraine.
- Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD [cannabidiol]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month.
- Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used.
- Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used.
- Participants affiliated with Sponsor or Contract Research Organization (CRO).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: CROSS_SECTIONAL
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Panadol/Dolex Tablet
Participants who have taken Panadol/Dolex for at least 1 headache episode in the past 1 month. |
Paracetamol 500 milligram (mg) taken orally. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pain Intensity Before Using Panadol/Dolex
Ramy czasowe: Within the past 1 month from time of participation
|
Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome. |
Within the past 1 month from time of participation
|
|
Perceived Relief From Panadol/Dolex Use
Ramy czasowe: Within the past 1 month from time of participation
|
Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex. |
Within the past 1 month from time of participation
|
|
QoL Assessment After Using Panadol/Dolex Post Headache Episode
Ramy czasowe: Within the past 1 month from time of participation
|
Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life. |
Within the past 1 month from time of participation
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Frequency of Panadol/Dolex Use
Ramy czasowe: Within the past 1 month from time of participation
|
Thinking about the recent headache episode, participants will be asked to mention the frequency of product use from 1 time a day to 4 times a day. |
Within the past 1 month from time of participation
|
|
Timepoint of Panadol/Dolex Use
Ramy czasowe: Within the past 1 month from time of participation
|
Participants will answer a single question related to timepoint of product use- 'Thinking about the same headache episode which you used Panadol for relief in the past one month, what did you first do to relieve the pain?' Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
Product Satisfaction
Ramy czasowe: Within the past 1 month from time of participation
|
Thinking about the experience of using Panadol, participants will rate their overall satisfaction on a scale 1 to 5, where 1= Absolutely dissatisfied and 5= Completely satisfied. |
Within the past 1 month from time of participation
|
|
Headache Management Behaviors
Ramy czasowe: Within the past 1 month from time of participation
|
Participants will answer a single question related to headache management approaches they used before- 'Thinking about similar headaches you experienced before this episode, what did you do to relieve your headache in the past?' Participants will select one or more descriptive options provided. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Trust in The Product
Ramy czasowe: Within the past 1 month from time of participation
|
Participants will answer a single question related to trust in the product- 'How much do you trust the product to provide fast headache pain relief?' Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Value For Money
Ramy czasowe: Within the past 1 month from time of participation
|
Thinking about experience of using the product, participants will be asked to rate the product's value for money on a scale 1 to 5, where 1= Poor value for money and 5= Excellent value for money. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Intention to Use Again
Ramy czasowe: Within the past 1 month from time of participation
|
Participants will answer a single question related to continued purchase- 'How likely would you choose Panadol again for your next headache episode?'. Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Intention to Recommend Other Consumers
Ramy czasowe: Within the past 1 month from time of participation
|
Participants will answer a single question related to likelihood to recommend others- How likely would you recommend Panadol to other consumers experiencing headache pain? Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 400384
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
Ramy czasowe udostępniania IPD
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Kryteria dostępu do udostępniania IPD
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .